GlobalData on MSN2d
23andMe weighing up sale of the company as cash runs dry
Me is considering a sale of the company as it weighs up strategic options, capping a torrid year for the genetic testing ...
23andMe Considers Sale as Cash Runs Low
The DNA-testing company is exploring its options, including a business combination and the sale of some or all of its assets.
23andMe launches new genetic report on osteoporosis
Holding released a new polygenic risk score report on the genetics of osteoporosis for 23andMe+ Premium members. The report ...
newsbytesapp.com2d
23andMe considers sale amid financial struggles and leadership turmoil
By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a ...
Nature9d
What went wrong at 23andMe? Why the genetic-data giant risks collapse
At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.
23andMe Reports Third Quarter Fiscal Year 2025 Financial Results
Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial ...
23andMe Board Explores Strategic Alternatives Amid Restructuring
23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, ...